ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 477

Impact of Etanercept On Incident Cancer in Taiwanese Patients with Rheumatoid Arthritis

Jiunn Horng Chen1 and Wen-Miin Liang2, 1Internal Medicine, China Medical University Hospital, Taichung City, Taiwan, 2Biostatistics Center, China Medical University, Taichung, Taiwan

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: etanercept and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy

Session Type: Abstract Submissions (ACR)

Background/Purpose: The recent Taiwanese report has indicated an elevated risk of malignancy in RA patients1. Etanercept, one of the tumor necrotic factor inhibitors (TNF-I) to treat severe rheumatoid arthritis (RA), has been approved in Taiwan for 10 years. Its effect in ameliorating inflammation in RA has been shown prominent. Although the potential risk of TNF-I on cancer in RA patients has been reported, the impact of TNF-I in Asian RA patients is still lacking. We used the National Health Insurance Database in Taiwan to investigate if etanercept impacts on incident cancer in RA patients.

Methods: A prospective one-to-one case-control study matched with age, gender, index day (prescription date of etanercept), RA duration (from the date of RA diagnosis to the index day), dosage and duration of methotrexate usage was conducted. Cancer incidence, including solid-tumor and hematological malignancy, was compared in RA patients between etanercept users and those who were naïve to the TNF-I. Cox proportional hazard model was used for analysis.

Results: Among the 1,931 matched pairs (3,180 women and 682 men with the mean age of 53.8 years) during a mean follow-up of 3.7 years, 36 subjects were found cancer in the case-cohort (31 solid-tumor and 5 hematologic malignancy), and 48 in the control-cohort (46 solid-tumor and 2 hematologic malignancy). The incidences of total cancer in subjects with RA duration within 1 year and 1-2 years were 37.0 x10-3 and 11.6 x10-3 person-years in the case-cohort, which were lower than those of 127.2 x10-3 and 27.9 x10-3 person-years in the control-cohort, respectively (the corresponding p=0.002 and 0.03). On the other hand, the incidences of total cancer in subjects with RA duration within 2-3 years and more than 3 years were 12.8 x10-3 and 2.8 x10-3 person-years in the case-cohort, which were higher than those of 6.7 x10-3 and 1.9 x10-3 person-years in the control-cohort, respectively (the corresponding p=0.15 and 0.35). The incidence of hematologic malignancy in the case-cohort was 0.95 x10-3 person-years, which was 2.5 times higher than that of 0.38 x10-3 person-years in the control-cohort (p=0.26). Although no statistically significant risk of etanercept was noted for total cancer after multivariate adjustment, hazard ratios for solid tumor and hematologic malignancy were 0.70 (95% confidence interval, 0.44-1.33) and 2.17 (0.42-11.23), respectively.

Conclusion: A potential benefit of etanercept was shown for patients with shorter RA duration by a trend of lower cancer incidence in the etanercept users compared with controls, which was contrasted to the findings noted for patients with RA duration more than 2 years. Although a trend of higher risk of hematologic malignancy for etanercept users than controls was noted in the current study, we may not conclude a significantly higher risk for RA patients received etanercept than those who received the convention treatment to develop cancer. Further investigation is needed in the future.

Reference Chen YJ, Chang YT, Wang CB, Wu CY. The risk of cancer in patients with rheumatoid arthritis: a nationwide cohort study in Taiwan. Arthritis Rheum. 2011;63(2):352-358.


Disclosure:

J. H. Chen,
None;

W. M. Liang,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-etanercept-on-incident-cancer-in-taiwanese-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology